These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17571579)

  • 1. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
    Kashiwagi H; Tomiyama Y
    Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
    [No Abstract]   [Full Text] [Related]  

  • 3. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
    Panzer S
    Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
    Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
    [No Abstract]   [Full Text] [Related]  

  • 5. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract]   [Full Text] [Related]  

  • 6. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
    Arnold DM; Nazi I; Kelton JG
    Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
    Pignatti F; Flores B; Jonsson B
    Am J Hematol; 2012 Oct; 87(10):943-4. PubMed ID: 22987253
    [No Abstract]   [Full Text] [Related]  

  • 10. [Autoimmune (idiopathic) thrombocytopenic purpura].
    Tomiyama Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1298-305. PubMed ID: 18833913
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 12. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
    Matzdorff A; Giagounidis A; Greinacher A; Hiller E; Kiefel V; Müller-Beissenhirtz H; Ostermann H; Rummel M; Sachs UJ; Salama A
    Onkologie; 2010; 33 Suppl 3():2-20. PubMed ID: 20484949
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet count or bleeding as the outcome in ITP trials?
    Arnold DM
    Am J Hematol; 2012 Oct; 87(10):945-6. PubMed ID: 22847526
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M
    Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
    [No Abstract]   [Full Text] [Related]  

  • 18. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A; Abrams CS
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract]   [Full Text] [Related]  

  • 20. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.